We recommend continuation of chronic beta-blocker therapy with AHF, unless the patient is symptomatic from hypotension or bradycardia (Recommendation Strong, Quality Moderate).

Values and Preferences This recommendation places higher value on the RCT evidence of efficacy and safety to continue beta-blockers, the ability of clinicians to use clinical judgment and lesser value on observational evidence for patients with AHF.